Vanguard Group Inc. Lowers Stake in TransMedics Group, Inc. $TMDX

Key Points

• Vanguard Group Inc. has reduced its stake in TransMedics Group, Inc. by 1.7% during the first quarter, owning approximately 10.57% of the company valued at $240.5 million.
• Insider trading activity includes sales by directors David Weill and Edward M. Basile, who sold shares valued at $90,680 and $632,250 respectively, representing significant decreases in their ownership.
• TransMedics Group reported earnings that exceeded analysts' expectations, with a revenue increase of 37.7% year-over-year, highlighting strong performance in their medical technology sector.

Vanguard Group Inc. decreased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 1.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,574,996 shares of the company's stock after selling 60,923 shares during the quarter. Vanguard Group Inc. owned about 10.57% of TransMedics Group worth $240,526,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in TMDX. Braidwell LP purchased a new position in shares of TransMedics Group in the fourth quarter worth $57,493,000. Mackenzie Financial Corp grew its stake in TransMedics Group by 73.0% during the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock valued at $51,635,000 after purchasing an additional 349,403 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of TransMedics Group by 1,565.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock valued at $16,820,000 after purchasing an additional 253,624 shares during the period. Avidity Partners Management LP lifted its holdings in shares of TransMedics Group by 597.1% during the fourth quarter. Avidity Partners Management LP now owns 192,400 shares of the company's stock worth $11,996,000 after purchasing an additional 164,800 shares during the period. Finally, Frontier Capital Management Co. LLC acquired a new position in TransMedics Group in the 4th quarter worth approximately $9,415,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Price Performance

TMDX stock traded up $0.3460 during trading on Friday, hitting $119.1560. The stock had a trading volume of 775,127 shares, compared to its average volume of 1,328,592. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The company's 50-day moving average price is $122.11 and its two-hundred day moving average price is $100.99. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. The stock has a market capitalization of $4.06 billion, a P/E ratio of 61.70 and a beta of 2.09.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. The firm had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The business's revenue was up 37.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. As a group, research analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on TMDX. Wall Street Zen upgraded shares of TransMedics Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Morgan Stanley upped their target price on TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Piper Sandler reiterated an "overweight" rating and set a $145.00 price target (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Finally, Oppenheimer boosted their price target on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $123.00.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 5,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total transaction of $632,250.00. Following the transaction, the director owned 2,866 shares in the company, valued at approximately $362,405.70. This trade represents a 63.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the sale, the insider owned 13,955 shares of the company's stock, valued at approximately $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.00% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.